ArticleJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2026
Use of DXA-derived 3D-modeling, as implemented by 3D-Shaper, for the assessment of fracture risk in a population-based setting.
Article in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Concerns regarding the critical evaluation of 3D-Shaper.JBMR plus · 2026Article
- Relationship between bone mineral density and strength derived from 3D-shaper and HR-pQCT in patients with X-linked osteoporosis related to PLS3.Archives of osteoporosis · 2026Article
- Critical evaluation of 3D-DXA and 3D-Shaper: methodological limitations and their implications.JBMR plus · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Three-dimensional modeling of hip DXA scans has been proposed to partition BMD into cortical surface (csBMD) and trabecular "volumetric" (tvBMD). We assessed in a population-based cohort, whether such partitioning contributes to fracture risk assessment compared to aBMD alone. Participants (N = 4908) from the Rotterdam Study comprised 56% women, with a mean age of 67.4 (SD = 10.1) years. Hip DXA scans were analyzed with enCore (GE Lunar) and 3D-Shaper software. Pearson partial correlation was calculated between aBMD, csBMD, and tvBMD at the total hip, femoral neck, and trochanter. Incident fractures were collected from GP or hospital records. During a mean follow-up of 6.8 (SD = 2.5) years, 171 sustained a hip fracture, and 1019 any-type fractures. Fracture risk estimates were determined as hazard ratios (HR) per SD decrease in BMD, from Cox-regression adjusted for multiple confounders. High correlation (r = >.81; p < .001) was observed between aBMD and the modeled 3D parameters, and between csBMD and tvBMD (r = 0.85; p < .001 at the total hip). Lower aBMD was associated with higher incidence of any-type (HR = 1.60, 95% CI: 1.43-1.78) and hip (HR = 2.46, 95% CI: 1.90-3.17) fracture; lower csBMD with increased risk of any-type (HR = 1.44, 95% CI: 1.30-1.60) and hip (csBMD HR = 1.76, 95% CI: 1.39-2.23) fracture; and tvBMD with increased risk of any-type (HR = 1.62, 95% CI: 1.45-1.80) and hip fracture (HR = 2.44, 95% CI: 1.88-3.15). Inclusion of aBMD in models with tvBMD or csBMD resulted in high multicollinearity and unreliable coefficient parameters (VIF > 5). The effect of csBMD was largely attenuated after inclusion of tvBMD in the same model for both any-type (csBMD HR = 0.96, 95% CI: 0.81-1.13; tvBMD HR = 1.67, 95% CI: 1.41-1.98) and hip (csBMD HR = 0.83, 95% CI: 0.58-1.21; tvBMD HR = 2.82, 95% CI: 1.94-4.10) fractures. Similar results were observed at the neck and intertrochanteric regions. DXA-derived 3D modeled parameters are highly correlated to aBMD and do not provide additional value for the estimation of fracture risk beyond aBMD alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.